PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Pfizer surpasses Wall Street expectations with strong fourth-quarter earnings. Sustained demand for older drugs offsets ...

As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.

Pfizer's fourth-quarter profits exceeded expectations, driven by strong demand for older drugs despite declining COVID-19 ...

Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...

Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.

Whereas conventional treatments such as chemotherapy and radiotherapy show their limitations in battling certain advanced ...